Plain-English translation of NCT04783441 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
After a kidney transplant, managing blood sugar can be harder because surgery, medications, and changes in diet and movement all affect your glucose levels. This study is testing whether a continuous glucose monitoring device called the Dexcom G6 helps transplant patients keep their blood sugar better controlled than checking it the old-fashioned way with finger sticks. The device sits on your skin and automatically measures your glucose throughout the day and night.
Many kidney transplant patients struggle to manage their blood sugar after surgery, and checking blood sugar by finger stick four or more times a day is burdensome and doesn't catch all the highs and lows. This trial wants to see if the automatic glucose monitor helps patients and their doctors spot patterns and adjust medications more effectively.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to either wear the continuous glucose monitor or continue checking your blood sugar with finger sticks four times a day. If you receive the monitor, you'll wear a small sensor on your skin that automatically measures your glucose levels throughout the day and night — you only need to do finger sticks if the device stops communicating or if your symptoms don't match what the device shows. Your care team will review the glucose patterns from the device to help adjust your medications. The study will track how well your blood sugar is controlled over time.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
United States
Sponsor
University of California, Davis
Collaborators
DexCom, Inc.
Enrollment target
~80 participants
Started
June 2021
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Dahlia Zuidema, PharmD
UCDavis Transplant Nephrology
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.